Jones T - Search Results

1

A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

Jones T, Allard F, Cyr SL, Tran SP, Plante M, Gauthier J, Bellerose N, Lowell GH, Burt DS. Jones T, et al. Vaccine. 2003 Sep 8;21(25-26):3706-12. doi: 10.1016/s0264-410x(03)00387-6. Vaccine. 2003. PMID: 12922101

2

Protollin: a novel adjuvant for intranasal vaccines.

Jones T, Cyr S, Allard F, Bellerose N, Lowell GH, Burt DS. Jones T, et al. Vaccine. 2004 Sep 9;22(27-28):3691-7. doi: 10.1016/j.vaccine.2004.03.035. Vaccine. 2004. PMID: 15315848

3

Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.

Jones T, Adamovicz JJ, Cyr SL, Bolt CR, Bellerose N, Pitt LM, Lowell GH, Burt DS. Jones T, et al. Vaccine. 2006 Mar 6;24(10):1625-32. doi: 10.1016/j.vaccine.2005.09.052. Epub 2005 Oct 7. Vaccine. 2006. PMID: 16243411

4

Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults.

Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, Mallett CP, Lowell GH, Fries L. Langley JM, et al. Among authors: jones t. Vaccine. 2006 Mar 6;24(10):1601-8. doi: 10.1016/j.vaccine.2005.09.056. Epub 2005 Oct 14. Vaccine. 2006. PMID: 16303215 Clinical Trial.

5

C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine.

Cyr SL, Jones T, Stoica-Popescu I, Burt D, Ward BJ. Cyr SL, et al. Among authors: jones t. Vaccine. 2007 Apr 20;25(16):3228-32. doi: 10.1016/j.vaccine.2007.01.037. Epub 2007 Jan 22. Vaccine. 2007. PMID: 17374422

6

Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.

Cyr SL, Jones T, Stoica-Popescu I, Brewer A, Chabot S, Lussier M, Burt D, Ward BJ. Cyr SL, et al. Among authors: jones t. Vaccine. 2007 Jul 20;25(29):5378-89. doi: 10.1016/j.vaccine.2007.05.004. Epub 2007 May 24. Vaccine. 2007. PMID: 17561317

7

Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.

Hu MC, Jones T, Kenney RT, Barnard DL, Burt DS, Lowell GH. Hu MC, et al. Among authors: jones t. Vaccine. 2007 Aug 21;25(34):6334-40. doi: 10.1016/j.vaccine.2007.06.017. Epub 2007 Jun 29. Vaccine. 2007. PMID: 17640780 Free PMC article.

8

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge.

Plante M, Jones T, Allard F, Torossian K, Gauthier J, St-Félix N, White GL, Lowell GH, Burt DS. Plante M, et al. Among authors: jones t. Vaccine. 2001 Oct 12;20(1-2):218-25. doi: 10.1016/s0264-410x(01)00268-7. Vaccine. 2001. PMID: 11567767

9

Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.

Knight JB, Huang YY, Halperin SA, Anderson R, Morris A, Macmillan A, Jones T, Burt DS, Van Nest G, Lee SF. Knight JB, et al. Among authors: jones t. Clin Exp Immunol. 2006 Jun;144(3):543-51. doi: 10.1111/j.1365-2249.2006.03097.x. Clin Exp Immunol. 2006. PMID: 16734625 Free PMC article.

10

The role of nasal IgA in children vaccinated with live attenuated influenza vaccine.

Ambrose CS, Wu X, Jones T, Mallory RM. Ambrose CS, et al. Among authors: jones t. Vaccine. 2012 Nov 6;30(48):6794-801. doi: 10.1016/j.vaccine.2012.09.018. Epub 2012 Sep 18. Vaccine. 2012. PMID: 23000125 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,032 results

Search Page

Filters